



## PEER-REVIEW REPORT

**Name of journal:** World Journal of Gastroenterology

**Manuscript NO:** 38483

**Title:** Establishment, functional and genetic characterization of a colon derived large cell neuroendocrine carcinoma cell line

**Reviewer's code:** 00008633

**Reviewer's country:** Japan

**Science editor:** Xue-Jiao Wang

**Date sent for review:** 2018-03-03

**Date reviewed:** 2018-03-18

**Review time:** 15 Days

| SCIENTIFIC QUALITY                                | LANGUAGE QUALITY  | CONCLUSION   | PEER-REVIEWER STATEMENTS                      |
|---|---|--|---|
| <input type="checkbox"/> Grade A: Excellent       | <input type="checkbox"/> Grade A: Priority publishing       | <input type="checkbox"/> Accept                    | Peer-Review:                                  |
| <input type="checkbox"/> Grade B: Very good       | <input checked="" type="checkbox"/> Grade B: Minor language | (High priority)                                    | <input checked="" type="checkbox"/> Anonymous |
| <input checked="" type="checkbox"/> Grade C: Good | polishing   | <input type="checkbox"/> Accept                    | <input type="checkbox"/> Onymous              |
| <input type="checkbox"/> Grade D: Fair            | <input type="checkbox"/> Grade C: A great deal of           | (General priority)                                 | Peer-reviewer's expertise on the              |
| <input type="checkbox"/> Grade E: Do not          | language polishing  | <input type="checkbox"/> Minor revision            | topic of the manuscript:                      |
| publish   | <input type="checkbox"/> Grade D: Rejection                 | <input checked="" type="checkbox"/> Major revision | <input type="checkbox"/> Advanced             |
|   |   | <input type="checkbox"/> Rejection                 | <input type="checkbox"/> General              |
|   |   |  | <input type="checkbox"/> No expertise         |
|   |   |  | Conflicts-of-Interest:                        |
|   |   |  | <input type="checkbox"/> Yes                  |
|   |   |  | <input type="checkbox"/> No                   |

### SPECIFIC COMMENTS TO AUTHORS

It is important to establish good NEC cell line. Major comments 1. The authors must clarify definition of the name of HROC57. Is it the name of cell line or resected tissue or both ? What is HROC57 B cell line ? 2. The authors must explain why they selected



**Baishideng  
Publishing  
Group**

7901 Stoneridge Drive, Suite 501,  
Pleasanton, CA 94588, USA  
**Telephone:** +1-925-223-8242  
**Fax:** +1-925-223-8243  
**E-mail:** bpgoffice@wjgnet.com  
**https://www.wjgnet.com**

HCT116, which is adenocarcinoma but not NEC, as control in Figure 1 ? 3. They should show results of CD26, CD29, CD73, and CD166 in Figure 2. 4. Although they wrote results of immunohistochemistry only in Table 1, they must show those pictures in Figure. 5. Discussion is too much long. They should shorten this section. 6. They wrote “Actual chemotherapeutic regimen for the treatment of advanced NEC consists of a combination of etoposide and cisplatin but results are very poor” in the first paragraph of Discussion. However, they wrote “HROC57 showed a high sensitivity towards etoposide and cisplatin with a distinct increase of sensitivity after combination of cisplatin and etoposide (Figure 4)”. Thus, this cell line might not reflect the nature of NEC.

#### **INITIAL REVIEW OF THE MANUSCRIPT**

##### ***Google Search:***

- The same title
- Duplicate publication
- Plagiarism
- No

##### ***BPG Search:***

- The same title
- Duplicate publication
- Plagiarism
- No